Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA ...

As the COVID-19 pandemic began to wreak havoc on the world in 2020, the biopharmaceutical industry started working tirelessly to develop a vaccine to stop this global threat. Emerging from this effort ...

Some genetic mutations that are expected to completely stop a gene from working surprisingly cause only mild or even no symptoms. Researchers in previous studies have discovered one reason why: cells ...

FDA issues a surprise refusal to review Moderna's mRNA-based flu vaccine filing, despite earlier agreement on trial design.

Researchers uncovered how cells coordinate genetic compensation when faulty mRNA is degraded. Small RNA fragments act as sequence “addresses” that recruit ILF3 to activate related backup genes.

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...

Stay ahead in the booming mRNA market, projected to reach $63.28 billion by 2025, with the 3 rd mRNA Process Development & Manufacturing Summit 2025 - Europe’s premier industry-focused forum dedicated ...

A new synthesis method offers hope for creation of advance mRNA vaccines to fight viruses and even cancers. Researchers at Nagoya University in Japan have developed a new chemical-only process that ...

LineaRx will present its Linea™ IVT platform - a combination of an enzymatically produced DNA template (Linea™ DNA IVT template) coupled with a next-generation RNA polymerase (Linea™ RNAP) - as a ...